Key Benefits
• Prevents type 2 diabetes (both prophylactic and therapeutic effects)
• Lowers fasting and postprandial blood glucose
• Improves glucose tolerance
• Protects pancreatic islet structure
• Boosts antioxidant enzyme levels and reduces oxidative stress
• Modulates inflammatory cytokines
Key Data
• Simulated gastric/intestinal fluid survival: >85% ; tolerates 0.3% bile salt
• Antioxidant capacity (DPPH, hydroxyl radical scavenging, anti‑lipid peroxidation) comparable to LGG
• In type 2 diabetic mice: fasting and 2h‑postprandial blood glucose significantly lower in both prevention and treatment groups vs. model
• AUC (glucose tolerance) significantly lower than model and drug groups (p < 0.05)
• Increases GSH, GSH‑Px, SOD; reduces ROS and MDA
• Protects islet morphology – more regular islets, uniform cell distribution, fewer pyknotic nuclei
Genome
Whole‑genome sequencing completed in 2015
Patent
National Invention Patent – Lactobacillus rhamnosus CCFM0528 with diabetes‑preventing effects
Commercial Use
Used in multiple products, including digestive health blends and metabolic health formulas (blood sugar, lipid, sleep, bone support)
Why Choose CCFM0528?
Specifically developed for diabetes prevention – a unique positioning in the probiotic market
Proven in both preventive and therapeutic animal models, giving formulators flexibility in product claims
Strong antioxidant and anti‑inflammatory effects support multiple health targets beyond glycemic control
Ideal for functional foods, dietary supplements, and meal replacements targeting pre‑diabetic and diabetic populations as well as metabolic syndrome consumers
Complete genome sequencing provides additional scientific credibility for regulatory submissions
